Novel RNA-Based Therapies in the Management of Dyslipidemias
International Journal of Molecular Sciences · 25.01.2025 · 26 (3) · 1026
DOI: 10.3390/ijms26031026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.01.2025. Verfasst von Constantine E Kosmas und 5 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Cardiology, National & Kapodistrian University of Athens, 12462 Athens, Greece. Hauptthemen laut MEDLINE: Dyslipidemias, RNA, Small Interfering, Genetic Therapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pharmaceutical advancements and an improved understanding of pathophysiology have enabled innovative therapies for chronic conditions like dyslipidemia. This condition is marked by abnormalities in lipid homeostasis. Nucleic acid therapeutics, including antisense oligonucleotides and small interfering RNAs, are novel management strategies that silence genes by targeting mRNA. Antisense oligonucleotides modify mRNA to inhibit protein production, whereas small interfering RNAs induce mRNA degradation via the RNA-induced silencing complex (RISC), thus offering promising treatments for dyslipidemia and atherosclerotic cardiovascular disease. Chemical modifications improve their stability and mRNA targeting. RNA-based therapies targeting PCSK9, Lp(a), ApoC-III, and ANGPTL3 hold transformative potential for treating dyslipidemia effectively. This article discusses the latest data from completed and ongoing trials on RNA therapies for dyslipidemia, including inclisiran, pelacarsen, olpasiran, zerlasiran, lepodisiran, volanesorsen, olezarsen, plozasiran, zodasiran, and solbinsiran. Each therapy targets specific molecules while also significantly impacting other lipid parameters. The promising results of these trials indicate potential improvements in lipid therapy and cardiovascular risk reduction, with ongoing studies expected to further refine the role of the novel RNA-based agents in effective lipid management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Department of Cardiology, National & Kapodistrian University of Athens, 12462 Athens, Greece.
- Health Center of Sofades, 43300 Karditsa, Greece.
- School of Medicine, University of Patras, 26504 Rio, Greece.
- General Directorate of Public Health and Social Welfare, Attica Region, 11521 Athens, Greece.
ORCID-Profile: Donatos Tsamoulis, Loukianos S Rallidis
Zitieren
APA
Kosmas, C. E., Bousvarou, M. D., Tsamoulis, D., Gianniou, M., Papakonstantinou, E. J., & Rallidis, L. S. (2025). Novel RNA-Based Therapies in the Management of Dyslipidemias. International Journal of Molecular Sciences, 26(3), 1026. https://doi.org/10.3390/ijms26031026
Vancouver
Kosmas CE, Bousvarou MD, Tsamoulis D, Gianniou M, Papakonstantinou EJ, Rallidis LS. Novel RNA-Based Therapies in the Management of Dyslipidemias. International Journal of Molecular Sciences. 2025;26(3):1026. doi:10.3390/ijms26031026
BibTeX
@article{Kosmas2025,
author = {Kosmas, Constantine E and Bousvarou, Maria D and Tsamoulis, Donatos and Gianniou, Maria and Papakonstantinou, Evangelia J and Rallidis, Loukianos S},
title = {Novel RNA-Based Therapies in the Management of Dyslipidemias},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {3},
pages = {1026},
doi = {10.3390/ijms26031026}
}
EUVIMED